Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Non-Current Assets of $6040.2 for Q1 2026, up 31.05% year-on-year from $4609.2 in Q1 2025, and down 7.71% on a QoQ basis from $6544.9 in Q4 2025.
Molecular Partners Ag (MOLN) Non-Current Assets (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Non-Current Assets for 7 consecutive years, with $6040.2 the latest figure, recorded in Q1 2026.
- Quarterly Non-Current Assets rose 31.05% year-over-year to $6040.2 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6040.2 (up 31.05% YoY) and the FY2025 annual result came in at $6544.9, up 35.0% from the prior year.
- Non-Current Assets declined to $6040.2 in Q1 2026 per MOLN's latest filing, from $6544.9 in the prior quarter.
- Over the last five years, Non-Current Assets for MOLN reached as high as $8.1 million in Q2 2022 and fell as low as $3987.8 in Q3 2025.
- A 5-year average of $1.2 million and a median of $6643.5 in 2023 frame the typical range for Non-Current Assets.
- The largest YoY upside for Non-Current Assets was 35.0% in 2025 against a maximum downside of 99.92% in 2025.
- Year by year, Non-Current Assets stood at $7791.4 in 2022, then declined by 14.73% to $6643.5 in 2023, then retreated by 27.03% to $4848.0 in 2024, then soared by 35.0% to $6544.9 in 2025, then decreased by 7.71% to $6040.2 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $6040.2, $6544.9, and $3987.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | 6,040.23 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,040.23 |
| Dec 31, 2025 | 6,544.87 |
| Sep 30, 2025 | 3,987.85 |
| Jun 30, 2025 | 4,452.28 |
| Mar 31, 2025 | 4,609.17 |
| Dec 31, 2024 | 4,848.04 |
| Sep 30, 2024 | 5,401.69 |
| Jun 30, 2024 | 5.54 Mn |
| Mar 31, 2024 | 6,208.45 |
| Dec 31, 2023 | 6,643.50 |
| Sep 30, 2023 | 7,002.36 |
| Jun 30, 2023 | 7.38 Mn |
| Mar 31, 2023 | 7,627.60 |
| Dec 31, 2022 | 7,791.39 |
| Sep 30, 2022 | 7,741.07 |
| Jun 30, 2022 | 8.11 Mn |
| Mar 31, 2022 | 8,915.84 |
| Dec 31, 2021 | 9,193.32 |
| Sep 30, 2021 | 9,489.58 |
| Dec 31, 2020 | 10,767.32 |